As reported on Business Wire, Onchilles Pharma has announced the first patient dosing in a Phase 1/2 clinical trial evaluating its investigational therapy, N17350, in individuals with advanced solid tumors. The milestone marks the company’s transition from preclinical development into clinical testing of its lead program.
N17350 is a tumor-targeted elastase engineered to selectively destroy cancer cells while sparing healthy tissues, particularly immune cells. This dual action is intended not only to directly reduce tumor burden but also to promote a systemic anti-tumor immune response. The therapy is built on the ELANE pathway, a mechanism believed to exploit a vulnerability in cancer cells associated with altered histone H1 biology.
The ongoing trial is designed as an open-label, dose-escalation and expansion study. Its primary objectives include evaluation of safety, tolerability, and identification of an appropriate dosing regimen. Secondary and exploratory endpoints will assess preliminary anti-tumor activity as well as biomarkers linked to immune activation. Patients enrolled in the study must have advanced solid tumors that can be accessed for intratumoral injection.
Preclinical evidence supporting N17350 demonstrated activity across multiple tumor models, including broad tumor cell killing, preservation of immune cell populations, and induction of immune responses targeting cancer. These findings underpin the rationale for advancing the therapy into first-in-human testing.
According to company leadership, the study aims to validate whether the selective and immune-stimulating properties observed in laboratory settings can translate into clinical benefit. The approach seeks to address a longstanding challenge in oncology: achieving effective tumor destruction without compromising immune function.
Clinical investigators have emphasized the need for therapies that both attack tumors directly and enhance immune-mediated responses, particularly in patients with advanced disease who have limited treatment options. N17350’s mechanism, which combines cytotoxicity with immunogenic effects, represents a novel strategy in this context.
Initially, the trial will focus on monotherapy use of N17350. Over time, the program may expand to include combination strategies, particularly alongside immunotherapies, as researchers explore synergistic effects.
Onchilles’ broader pipeline also includes NEU-002, a follow-on program designed to deliver similar ELANE pathway–based activity through systemic administration. Together, these programs aim to provide treatment options that are effective across a wide range of solid tumors regardless of genetic profile or tumor origin.
The company positions its ELANE-targeting approach as a potential alternative to traditional chemotherapy and immunotherapy, which can be limited by toxicity or variable response rates. By selectively inducing immunogenic cancer cell death, these therapies may offer a more targeted and durable anti-cancer strategy.
The current trial represents an early but important step in determining whether this mechanism can achieve meaningful clinical outcomes in patients with advanced malignancies.
